Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Kyoung Im | - |
dc.contributor.author | Sakuma, Ichiro | - |
dc.contributor.author | Sohn, Il Suk | - |
dc.contributor.author | Hayashi, Toshio | - |
dc.contributor.author | Shimada, Kazunori | - |
dc.contributor.author | Koh, Kwang Kon | - |
dc.date.available | 2020-02-27T11:41:01Z | - |
dc.date.created | 2020-02-07 | - |
dc.date.issued | 2018-04 | - |
dc.identifier.issn | 1346-9843 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/3880 | - |
dc.description.abstract | Statins are important for preventing adverse cardiovascular events in patients with both high and low risk of vascular disease, by reducing the levels of low-density lipoprotein cholesterol (LDL-C). However, statins dose-dependently increase adverse effects and increase the risk of type 2 diabetes. Previously, it was hypothesized this was caused by to off-target effects, but recent studies demonstrate it is caused by on-target effects. Nonetheless, the American guidelines recommend the use of high-intensity statin therapy, and extend its use to most people at risk of vascular diseases, particularly older people. In contrast, European, Korean, and Japanese committees have expressed concerns about the potential adverse effects of using high-intensity statins for lifelong periods in a large fraction of the population. Patients who have achieved LDL-C levels below currently recommended targets may still experience cardiovascular events, resulting from residual risk. Ezetimibe, PCSK9 inhibitors, inclisiran, and ANGPTL3 antisense oligonucleotides are promising alternative non-statin drugs. Of interest, cross-talk between hypercholesterolemia and the renin-angiotensin-system exists at multiple levels of insulin resistance and endothelial dysfunction. There are still unanswered questions on how to maximize the cardiometabolic benefits of statins in patients. We will discuss the results of randomized clinical trials, meta-analysis, and recent clinicopharmacogenetic studies, and propose practical guidelines to maximize the cardiometabolic benefits while reducing adverse effects and overcoming residual risk. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | JAPANESE CIRCULATION SOC | - |
dc.relation.isPartOf | CIRCULATION JOURNAL | - |
dc.subject | DENSITY-LIPOPROTEIN-CHOLESTEROL | - |
dc.subject | ANGIOTENSIN SYSTEM INHIBITOR | - |
dc.subject | ACUTE MYOCARDIAL-INFARCTION | - |
dc.subject | REDUCES ADIPONECTIN LEVELS | - |
dc.subject | FLOW-MEDIATED DILATION | - |
dc.subject | CARDIOVASCULAR-DISEASE | - |
dc.subject | INSULIN SENSITIVITY | - |
dc.subject | PRIMARY PREVENTION | - |
dc.subject | LDL-CHOLESTEROL | - |
dc.subject | VASCULAR EVENTS | - |
dc.title | Best Treatment Strategies With Statins to Maximize the Cardiometabolic Benefits | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000428079000001 | - |
dc.identifier.doi | 10.1253/circj.CJ-17-1445 | - |
dc.identifier.bibliographicCitation | CIRCULATION JOURNAL, v.82, no.4, pp.937 - 943 | - |
dc.identifier.scopusid | 2-s2.0-85044338447 | - |
dc.citation.endPage | 943 | - |
dc.citation.startPage | 937 | - |
dc.citation.title | CIRCULATION JOURNAL | - |
dc.citation.volume | 82 | - |
dc.citation.number | 4 | - |
dc.contributor.affiliatedAuthor | Koh, Kwang Kon | - |
dc.type.docType | Review | - |
dc.subject.keywordAuthor | Cardiovascular disease | - |
dc.subject.keywordAuthor | Non-statins | - |
dc.subject.keywordAuthor | Residual risk | - |
dc.subject.keywordAuthor | Statins | - |
dc.subject.keywordAuthor | Type 2 diabetes mellitus | - |
dc.subject.keywordPlus | DENSITY-LIPOPROTEIN-CHOLESTEROL | - |
dc.subject.keywordPlus | ANGIOTENSIN SYSTEM INHIBITOR | - |
dc.subject.keywordPlus | ACUTE MYOCARDIAL-INFARCTION | - |
dc.subject.keywordPlus | REDUCES ADIPONECTIN LEVELS | - |
dc.subject.keywordPlus | FLOW-MEDIATED DILATION | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | INSULIN SENSITIVITY | - |
dc.subject.keywordPlus | PRIMARY PREVENTION | - |
dc.subject.keywordPlus | LDL-CHOLESTEROL | - |
dc.subject.keywordPlus | VASCULAR EVENTS | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.